Q1 2026 Coloplast A/S Earnings Call Transcript
Key Points
- Coloplast AS (CLPBF) reported a 6% organic revenue growth and a 3% EBIT growth in constant currencies before special items.
- Interventional Urology delivered a strong start with 8% organic growth, driven by the Men's Health business.
- The company maintained its guidance of around 7% organic growth for the year.
- Coloplast AS (CLPBF) is enhancing its product portfolio in urology through an acquisition, expected to positively impact financial metrics in the second half of the strategic period.
- The company is optimistic about the long-term outlook for Kerecis, citing its unique technology and strong clinical documentation.
- Kerecis faced significant sales disruption due to Medicare reimbursement changes, resulting in negative growth in the outpatient setting.
- The EBIT margin for Kerecis was only 1% in the quarter, impacted by market uncertainty and one-off costs.
- Ostomy Care experienced a soft start with only 4% organic growth, affected by negative growth in China and high baseline in the U.S.
- The advanced wound dressings business declined by 3% in Q1, with China detracting significantly from growth.
- Reported revenue growth in Danish kroner was impacted by foreign exchange rates, reducing reported revenue by 4%.
Ladies and gentlemen, welcome to the Coloplast interim financial statement for Q1 2025, '26 conference call. I'm already chorus call operator. I would like to remind you that all participants will be in listen-only mode, and the conference has been recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.
At this time, it's my pleasure to hand over to Lars Rasmussen, Interim CEO.
/- -
Thank you, and good morning, and welcome to our Q1 '25, '26 conference call. I'm Lars Rasmussen, Interim CEO of Coloplast. And I'm joined by CFO, Anders Lonning-Skovgaard; and our Investor Relations team. We will start with a short presentation by Anders and myself and then open up for questions. And please turn to Slide number 3.
We delivered 6% organic revenue growth and 3% EBIT growth in constant currencies before special items. Return on invested
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
